MeSH term
Frequency | Condition_Probility | Aged | 299 | 0.0 |
Aged, 80 and over | 98 | 1.0 |
Fatal Outcome | 3 | 0.0 |
Female | 464 | 0.0 |
Humans | 1216 | 0.0 |
Tomography, X-Ray Computed | 5 | 0.0 |
Animals | 244 | 0.0 |
*Colorectal Neoplasms/diagnosis/metabolism/pathology/therapy | 2 | 3.0 |
Biopsy | 5 | 0.0 |
*Gene Expression | 2 | 0.0 |
*Lymphocytes, Tumor-Infiltrating | 2 | 12.0 |
Lymphoma, Follicular/*genetics/immunology | 2 | 20.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Clinical Trials | 4 | 0.0 |
Gene Therapy | 7 | 2.0 |
Recombinant Proteins/therapeutic use | 4 | 1.0 |
Adolescent | 68 | 0.0 |
Adult | 354 | 0.0 |
Case-Control Studies | 38 | 0.0 |
Comparative Study | 157 | 0.0 |
Male | 470 | 0.0 |
Middle Aged | 395 | 0.0 |
Time Factors | 73 | 0.0 |
Treatment Outcome | 23 | 0.0 |
Amino Acid Sequence | 160 | 0.0 |
*CDC2-CDC28 Kinases | 3 | 0.0 |
Gene Products, tat/chemistry/*physiology | 4 | 100.0 |
HIV-1/*genetics | 122 | 38.0 |
Hela Cells | 140 | 2.0 |
Molecular Sequence Data | 252 | 0.0 |
Phosphorylation | 29 | 0.0 |
*Promoter Regions (Genetics) | 27 | 1.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
Repetitive Sequences, Amino Acid | 3 | 2.0 |
Research Support, Non-U.S. Gov't | 639 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 291 | 0.0 |
*Transcription, Genetic | 49 | 2.0 |
Acute Disease | 32 | 1.0 |
Antifibrinolytic Agents/*blood | 2 | 40.0 |
Antiplasmin | 3 | 100.0 |
Antithrombin III | 46 | 83.0 |
Biological Markers/blood | 83 | 5.0 |
English Abstract | 97 | 0.0 |
Fibrin Fibrinogen Degradation Products/*metabolism | 7 | 33.0 |
Hemostasis | 24 | 23.0 |
Logistic Models | 3 | 0.0 |
Peptide Fragments/*blood | 5 | 6.0 |
Peptide Hydrolases/*blood | 9 | 81.0 |
Plasmin | 5 | 38.0 |
Prothrombin | 24 | 50.0 |
Sensitivity and Specificity | 20 | 0.0 |
Statistics, Nonparametric | 14 | 1.0 |
Base Sequence | 171 | 0.0 |
Gene Products, tat/*antagonists & inhibitors/metabolism | 4 | 80.0 |
HIV Long Terminal Repeat/*genetics | 28 | 38.0 |
Kinetics | 40 | 0.0 |
Nucleic Acid Conformation | 47 | 9.0 |
Transcription, Genetic/*drug effects | 9 | 2.0 |
Anticoagulants/administration & dosage | 4 | 28.0 |
Blood Coagulation/drug effects | 14 | 12.0 |
Disseminated Intravascular Coagulation/blood/*drug therapy | 2 | 100.0 |
Double-Blind Method | 17 | 1.0 |
Heparin/*administration & dosage | 7 | 22.0 |
Regression Analysis | 10 | 0.0 |
Stress, Psychological/*blood | 2 | 40.0 |
Fibrinogen/*metabolism | 6 | 8.0 |
Follow-Up Studies | 18 | 0.0 |
Thrombin/*metabolism | 19 | 24.0 |
Administration, Oral | 9 | 0.0 |
*Coronary Artery Bypass | 7 | 9.0 |
Fibrinogen/analysis | 24 | 13.0 |
Hemostasis/*drug effects | 14 | 21.0 |
Child | 34 | 0.0 |
Child, Preschool | 29 | 0.0 |
Prednisolone/therapeutic use | 2 | 2.0 |
Stress, Mechanical | 2 | 0.0 |
von Willebrand Factor/metabolism | 9 | 3.0 |
Hematocrit | 5 | 1.0 |
Hemoglobins/analysis | 2 | 0.0 |
Blood Coagulation/*drug effects | 37 | 30.0 |
Blood Coagulation Factors/metabolism | 15 | 27.0 |
Catalysis | 2 | 0.0 |
Platelet Activation | 6 | 4.0 |
Substrate Specificity | 6 | 0.0 |
Thromboplastin/*pharmacology | 4 | 30.0 |
CDK9 Protein Kinase | 17 | 25.0 |
Dichlororibofuranosylbenzimidazole/pharmacology | 5 | 18.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Gene Products, tat/*genetics/metabolism | 12 | 85.0 |
HIV-1/*genetics/metabolism | 10 | 37.0 |
Peptide Fragments/genetics/metabolism | 3 | 2.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Transcription, Genetic | 67 | 1.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Cell Line | 128 | 0.0 |
Cyclin-Dependent Kinases/*metabolism | 4 | 1.0 |
Gene Products, tat/*metabolism | 76 | 80.0 |
HIV Long Terminal Repeat/genetics | 19 | 41.0 |
HIV-1/enzymology/*genetics | 3 | 60.0 |
Plasmids | 39 | 3.0 |
Positive Transcriptional Elongation Factor B | 28 | 47.0 |
Protein-Serine-Threonine Kinases/*metabolism | 19 | 2.0 |
RNA Polymerase II/chemistry/*metabolism | 2 | 10.0 |
AIDS Vaccines/*immunology | 4 | 13.0 |
Gene Products, tat/*immunology | 3 | 42.0 |
HIV Antibodies/*blood | 2 | 5.0 |
HIV Long Terminal Repeat | 53 | 39.0 |
Immunization | 5 | 1.0 |
Macaca | 3 | 3.0 |
Mice | 77 | 0.0 |
Mice, Inbred BALB C | 9 | 0.0 |
Rabbits | 12 | 0.0 |
Trans-Activation (Genetics) | 63 | 3.0 |
Virus Replication | 27 | 3.0 |
Apoptosis | 5 | 0.0 |
Cell Line, Tumor | 6 | 0.0 |
Flow Cytometry | 18 | 0.0 |
Mice, Nude | 3 | 0.0 |
Neoplasm Metastasis | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 37 | 0.0 |
*Genes, Viral | 9 | 4.0 |
In Vitro | 32 | 0.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Mice, Transgenic | 14 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Alleles | 5 | 0.0 |
Genetic Markers | 3 | 0.0 |
*Variation (Genetics) | 6 | 0.0 |
*Y Chromosome | 2 | 1.0 |
Cyclins/*metabolism | 9 | 3.0 |
HIV Long Terminal Repeat/*physiology | 4 | 66.0 |
HIV-1/*metabolism | 22 | 9.0 |
Macromolecular Substances | 17 | 0.0 |
Mutation | 48 | 0.0 |
*Nucleic Acid Conformation | 9 | 9.0 |
Protein Binding | 72 | 0.0 |
*Gene Expression Regulation, Viral | 47 | 15.0 |
Gene Products, tat/genetics/*physiology | 10 | 71.0 |
HIV Infections/virology | 2 | 2.0 |
HIV-1/genetics/*physiology | 11 | 10.0 |
*Virus Replication | 17 | 6.0 |
Breast Neoplasms/*blood/*drug therapy | 2 | 40.0 |
Dose-Response Relationship, Drug | 38 | 0.0 |
Prospective Studies | 53 | 1.0 |
Tissue Plasminogen Activator/blood | 24 | 23.0 |
Age Factors | 6 | 0.0 |
*Blood Coagulation | 82 | 38.0 |
Fibrin Fibrinogen Degradation Products/analysis | 82 | 63.0 |
Peptide Fragments/blood | 23 | 21.0 |
Peptide Hydrolases/blood | 36 | 81.0 |
Thrombophilia/blood/diagnosis/etiology | 2 | 66.0 |
Cardiopulmonary Bypass | 6 | 13.0 |
*Extracorporeal Circulation | 5 | 20.0 |
Postoperative Period | 17 | 5.0 |
Antifibrinolytic Agents/metabolism | 15 | 71.0 |
Antiplasmin/metabolism | 14 | 51.0 |
Antithrombin III/metabolism | 60 | 50.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 44 | 50.0 |
*Fibrinolysis | 59 | 44.0 |
Immunoenzyme Techniques | 10 | 0.0 |
Peptide Hydrolases/metabolism | 53 | 36.0 |
Plasmin/metabolism | 28 | 32.0 |
Renal Dialysis | 5 | 1.0 |
Gene Expression Regulation, Viral | 45 | 16.0 |
Gene Products, tat/*physiology | 28 | 77.0 |
*HIV Long Terminal Repeat | 42 | 46.0 |
Molecular Weight | 10 | 0.0 |
RNA, Messenger/analysis | 6 | 0.0 |
*RNA-Binding Proteins | 3 | 0.0 |
*Trans-Activation (Genetics) | 61 | 8.0 |
Viral Proteins/*physiology | 2 | 6.0 |
Acetylation | 11 | 2.0 |
Blotting, Western | 17 | 0.0 |
Histones/metabolism | 3 | 1.0 |
Mutation/genetics | 7 | 0.0 |
Promoter Regions (Genetics)/genetics | 11 | 1.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Terminal Repeat Sequences/genetics | 2 | 14.0 |
Transcription Factors/genetics/*metabolism | 4 | 0.0 |
Transfection | 89 | 0.0 |
Gene Products, tat/chemistry/genetics/*metabolism | 5 | 100.0 |
HIV-1/genetics/metabolism | 2 | 22.0 |
Magnetic Resonance Spectroscopy | 9 | 1.0 |
Models, Molecular | 21 | 0.0 |
Molecular Structure | 11 | 1.0 |
*Protein Structure, Tertiary | 2 | 1.0 |
Sequence Alignment | 13 | 0.0 |
Blood Coagulation Disorders/*etiology | 8 | 40.0 |
Fibrinolysis | 38 | 24.0 |
Anticoagulants/*administration & dosage | 9 | 21.0 |
Injections, Subcutaneous | 4 | 1.0 |
Tedelparin/*administration & dosage | 3 | 60.0 |
Cells, Cultured | 71 | 0.0 |
Gene Products, tat/*pharmacology | 14 | 70.0 |
*HIV-1 | 23 | 2.0 |
Interleukin-10/*biosynthesis | 2 | 3.0 |
Protein Transport | 6 | 0.0 |
Colorectal Neoplasms/*blood/complications/surgery | 2 | 100.0 |
Fibrin/metabolism | 10 | 16.0 |
Predictive Value of Tests | 24 | 1.0 |
Severity of Illness Index | 9 | 0.0 |
Tumor Markers, Biological/blood | 3 | 1.0 |
Cell Nucleus/*metabolism | 7 | 1.0 |
Cyclin-Dependent Kinases/metabolism | 8 | 2.0 |
Cyclins/metabolism | 9 | 2.0 |
DNA-Binding Proteins/genetics/*metabolism | 8 | 0.0 |
Gene Products, tat/genetics/*metabolism | 31 | 73.0 |
Genes, Reporter | 17 | 0.0 |
Promoter Regions (Genetics) | 42 | 0.0 |
Protein Structure, Tertiary | 15 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 3 | 1.0 |
*Transcription Factors | 11 | 0.0 |
HIV Antibodies/blood | 2 | 2.0 |
HIV Infections/*prevention & control/virology | 2 | 40.0 |
Lymphocytes/immunology | 2 | 0.0 |
DNA Primers | 18 | 0.0 |
DNA, Viral/metabolism | 2 | 2.0 |
HIV-1/genetics/*metabolism | 25 | 37.0 |
RNA, Viral/metabolism | 8 | 9.0 |
Templates, Genetic | 9 | 5.0 |
Liver/*metabolism | 5 | 1.0 |
Particle Size | 2 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Binding, Competitive | 10 | 0.0 |
Ligands | 5 | 0.0 |
*Proteasome Endopeptidase Complex | 6 | 9.0 |
Virulence | 5 | 2.0 |
Antibodies, Antiphospholipid/*blood | 3 | 13.0 |
Biological Markers | 36 | 2.0 |
Cohort Studies | 16 | 0.0 |
Factor VIIa/metabolism | 6 | 12.0 |
Factor XIIa/metabolism | 2 | 50.0 |
Lipids/blood | 3 | 0.0 |
Peptide Fragments/metabolism | 17 | 4.0 |
Pregnancy | 38 | 0.0 |
Prothrombin/metabolism | 17 | 22.0 |
HIV Envelope Protein gp41/pharmacology | 2 | 50.0 |
HIV Infections/immunology/virology | 2 | 7.0 |
HIV-1/*immunology | 10 | 2.0 |
Up-Regulation | 5 | 0.0 |
HIV Core Protein p24/biosynthesis | 2 | 4.0 |
Receptors, CCR5/metabolism | 2 | 1.0 |
Tumor Cells, Cultured | 39 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 37 | 0.0 |
Antithrombin III/analysis | 120 | 64.0 |
Feedback | 2 | 1.0 |
Peptide Fragments/analysis | 36 | 15.0 |
Peptide Hydrolases/analysis | 109 | 83.0 |
Prothrombin/analysis | 41 | 54.0 |
Albuminuria/epidemiology | 2 | 25.0 |
Blood Pressure | 7 | 1.0 |
Insulin/blood | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 3 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Triglycerides/blood | 8 | 0.0 |
Leukocyte Count | 5 | 0.0 |
Monocytes | 4 | 4.0 |
Osmolar Concentration | 9 | 1.0 |
Calcium/*metabolism | 3 | 0.0 |
HIV-1 | 7 | 3.0 |
Monocytes/*metabolism | 2 | 0.0 |
NF-kappa B/physiology | 2 | 2.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Endothelium, Vascular/*metabolism | 4 | 1.0 |
HIV-1/*physiology | 35 | 7.0 |
NF-kappa B/*metabolism | 9 | 1.0 |
Recombinant Proteins/metabolism | 19 | 0.0 |
Cloning, Molecular | 46 | 0.0 |
*Escherichia coli Proteins | 13 | 5.0 |
Phylogeny | 9 | 0.0 |
Protein Subunits | 3 | 0.0 |
Sequence Homology, Amino Acid | 26 | 0.0 |
Species Specificity | 12 | 0.0 |
Infant | 17 | 0.0 |
Infant, Newborn | 19 | 0.0 |
Anticoagulants/administration & dosage/*therapeutic use | 5 | 35.0 |
Enoxaparin/administration & dosage/*therapeutic use | 2 | 100.0 |
Factor Xa/antagonists & inhibitors | 3 | 6.0 |
Lipoproteins/analysis | 3 | 13.0 |
Postoperative Complications/*prevention & control | 2 | 11.0 |
Risk | 4 | 0.0 |
Risk Factors | 39 | 0.0 |
Single-Blind Method | 4 | 1.0 |
Tedelparin/administration & dosage/*therapeutic use | 2 | 100.0 |
Thrombosis/*prevention & control | 3 | 16.0 |
Aspirin/pharmacology | 2 | 3.0 |
Exercise/*physiology | 9 | 2.0 |
Exercise Test | 4 | 1.0 |
Plasminogen Activator Inhibitor 1/blood | 31 | 26.0 |
Platelet Aggregation Inhibitors/pharmacology | 2 | 3.0 |
Thrombin/*biosynthesis | 13 | 39.0 |
Antithrombins/analysis | 6 | 37.0 |
Blood Coagulation/*physiology | 46 | 39.0 |
Preoperative Care | 5 | 3.0 |
beta-Thromboglobulin/analysis | 9 | 10.0 |
Peptide Fragments/drug effects/metabolism | 2 | 33.0 |
Prothrombin/drug effects/metabolism | 2 | 66.0 |
DNA/metabolism | 8 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 14 | 0.0 |
Glutathione Transferase/metabolism | 7 | 0.0 |
Nuclear Proteins/*metabolism | 6 | 0.0 |
Plasmids/metabolism | 6 | 0.0 |
Recombinant Fusion Proteins/metabolism | 17 | 1.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
Trans-Activators/*metabolism | 9 | 0.0 |
Antithrombins/*metabolism | 4 | 40.0 |
Down-Regulation | 6 | 0.0 |
Protein C/*metabolism | 6 | 3.0 |
Protein Precursors/analysis | 10 | 23.0 |
Thrombin/analysis/*metabolism | 2 | 100.0 |
Venous Thrombosis/*blood | 2 | 16.0 |
Acute-Phase Reaction/*blood | 2 | 7.0 |
Blood Coagulation Factors/*metabolism | 13 | 16.0 |
*Convalescence | 2 | 50.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/*metabolism | 3 | 4.0 |
Gene Products, tat/*genetics/immunology | 2 | 100.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
Gestational Age | 10 | 1.0 |
Pregnancy Trimester, Second | 2 | 0.0 |
ROC Curve | 3 | 1.0 |
Blood Pressure/physiology | 2 | 1.0 |
Gene Deletion | 5 | 0.0 |
Gene Expression | 21 | 0.0 |
Antiplasmin/analysis | 24 | 64.0 |
Longitudinal Studies | 4 | 0.0 |
Plasmin/analysis | 31 | 72.0 |
Thrombin/metabolism | 18 | 12.0 |
Reference Values | 31 | 0.0 |
Thrombin/*physiology | 4 | 19.0 |
Area Under Curve | 2 | 0.0 |
Biotinylation | 2 | 1.0 |
Injections, Intravenous | 5 | 0.0 |
Metabolic Clearance Rate | 3 | 0.0 |
Rats | 46 | 0.0 |
Blood Flow Velocity | 4 | 4.0 |
Echocardiography, Transesophageal | 5 | 35.0 |
Ultrasonography, Doppler | 2 | 7.0 |
Binding Sites | 67 | 0.0 |
Enhancer Elements (Genetics) | 7 | 1.0 |
Jurkat Cells | 25 | 1.0 |
Luciferases/metabolism | 4 | 0.0 |
Mammary Tumor Virus, Mouse/genetics | 2 | 5.0 |
Models, Biological | 12 | 0.0 |
Models, Genetic | 10 | 0.0 |
Transcription Factors/metabolism | 9 | 0.0 |
Endothelium, Vascular/*physiology | 2 | 1.0 |
*Hemostasis | 30 | 23.0 |
Homocysteine/*blood | 2 | 0.0 |
Thrombosis/etiology | 6 | 9.0 |
Interleukin-1/metabolism | 4 | 1.0 |
Tumor Necrosis Factor-alpha/metabolism | 7 | 0.0 |
Blood Coagulation Tests/*standards | 2 | 40.0 |
International Normalized Ratio | 3 | 10.0 |
Warfarin/administration & dosage | 2 | 66.0 |
Whole Blood Coagulation Time | 7 | 41.0 |
Drug Evaluation, Preclinical/*methods | 2 | 6.0 |
Gene Products, tat/*antagonists & inhibitors/chemistry/metabolism | 2 | 100.0 |
Molecular Mimicry | 3 | 4.0 |
RNA, Viral/genetics/metabolism | 7 | 29.0 |
Temperature | 8 | 0.0 |
Acetyltransferases/genetics/*metabolism | 2 | 8.0 |
Lysine/metabolism | 2 | 2.0 |
Nucleosomes/*metabolism | 2 | 5.0 |
*Saccharomyces cerevisiae Proteins | 16 | 1.0 |
Transcription Factors/genetics | 5 | 0.0 |
Virus Integration | 3 | 4.0 |
Gene Products, tat/metabolism/*pharmacology | 4 | 66.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Myocardial Infarction/*blood | 4 | 6.0 |
Protein C Inhibitor/*blood | 3 | 100.0 |
Aspirin/administration & dosage | 2 | 28.0 |
Fibrinogen/metabolism | 20 | 9.0 |
Hypertension/epidemiology | 2 | 4.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Smoking | 2 | 0.0 |
Cell-Free System | 7 | 2.0 |
*Gene Expression Regulation | 10 | 0.0 |
*Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 3 | 12.0 |
Heterogeneous-Nuclear Ribonucleoproteins | 4 | 3.0 |
*Nuclear Proteins | 6 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
RNA, Viral/biosynthesis/genetics | 2 | 22.0 |
Regulatory Sequences, Nucleic Acid | 16 | 2.0 |
Spliceosomes/metabolism | 2 | 9.0 |
Antigens/blood | 4 | 7.0 |
Disseminated Intravascular Coagulation/blood/*etiology | 2 | 66.0 |
Fibrinolysis/*physiology | 39 | 51.0 |
Thrombophilia/*blood | 4 | 80.0 |
Varicose Veins/*blood | 2 | 66.0 |
Gene Products, tat/*genetics | 26 | 66.0 |
Gene Silencing | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 3 | 3.0 |
Gene Products, tat/metabolism | 22 | 59.0 |
HIV-1/*genetics/*metabolism | 10 | 66.0 |
Precipitin Tests | 8 | 0.0 |
RNA Polymerase II/metabolism | 7 | 6.0 |
Transcription Factors/*metabolism | 19 | 1.0 |
*Transcription Factors, TFII | 8 | 7.0 |
P-Selectin/blood | 3 | 4.0 |
*Platelet Activation | 8 | 5.0 |
Vascular Cell Adhesion Molecule-1/blood | 3 | 5.0 |
Anti-HIV Agents/chemistry/*pharmacology | 2 | 10.0 |
Transcription, Genetic/drug effects | 5 | 0.0 |
Alu Elements/genetics | 2 | 7.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Y Chromosome/*genetics | 3 | 4.0 |
Electrocardiography | 6 | 1.0 |
Risk Assessment | 2 | 0.0 |
Cholesterol/blood | 8 | 0.0 |
Head and Neck Neoplasms/surgery | 2 | 50.0 |
*Hemostasis/drug effects | 3 | 100.0 |
Infusions, Intravenous | 10 | 1.0 |
Cyclins/genetics/*metabolism | 4 | 4.0 |
Gene Library | 5 | 0.0 |
RNA, Viral/*metabolism | 17 | 39.0 |
Recombinant Fusion Proteins/genetics/metabolism | 13 | 1.0 |
Antithrombin III/*analysis | 57 | 69.0 |
Pregnancy Trimester, Third | 4 | 2.0 |
Statistics | 5 | 1.0 |
Atrial Function, Left | 2 | 66.0 |
Chronic Disease | 18 | 1.0 |
Thrombophilia/blood/diagnosis/*etiology | 2 | 100.0 |
Acetyltransferases/metabolism | 3 | 4.0 |
Gene Products, tat/chemistry/*genetics/metabolism | 2 | 100.0 |
Proviruses/genetics | 6 | 9.0 |
DNA-Binding Proteins/metabolism | 7 | 0.0 |
NF-kappa B/genetics/*metabolism | 3 | 4.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
RNA Polymerase II/*metabolism | 12 | 12.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
Vaccinia virus/genetics | 2 | 2.0 |
Cell Nucleus/metabolism | 12 | 0.0 |
*Exons | 8 | 2.0 |
Mutagenesis, Site-Directed | 32 | 1.0 |
*RNA Splicing | 14 | 5.0 |
Sequence Homology, Nucleic Acid | 12 | 0.0 |
Plasmin/*metabolism | 9 | 34.0 |
Sex Factors | 2 | 0.0 |
Venous Thrombosis/blood/etiology | 2 | 66.0 |
Inflammation/blood | 3 | 5.0 |
Interleukin-6/blood | 5 | 1.0 |
Prognosis | 24 | 0.0 |
Enzyme Induction/drug effects | 5 | 1.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Interleukin-6/pharmacology | 3 | 1.0 |
Antigens/analysis | 4 | 2.0 |
Aging/*blood | 2 | 2.0 |
Blood Coagulation/physiology | 9 | 15.0 |
Blood Platelets/physiology | 3 | 5.0 |
Hemoglobins/metabolism | 5 | 3.0 |
Hemostasis/*physiology | 13 | 23.0 |
Cysteine Endopeptidases/physiology | 2 | 8.0 |
*I-kappa B | 2 | 1.0 |
Multienzyme Complexes/physiology | 2 | 8.0 |
Proteasome Endopeptidase Complex | 5 | 0.0 |
Chromatography, High Pressure Liquid | 8 | 0.0 |
Platelet Activation/*physiology | 3 | 5.0 |
Biological Markers/analysis | 12 | 1.0 |
Cell Count | 2 | 0.0 |
Cross-Sectional Studies | 11 | 0.0 |
Immunoglobulin G/analysis | 6 | 1.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 2 | 5.0 |
Recurrence | 9 | 0.0 |
Laparoscopy/*adverse effects | 2 | 22.0 |
Plasminogen/metabolism | 6 | 15.0 |
Protein C/metabolism | 10 | 11.0 |
Enoxaparin/administration & dosage/pharmacology | 2 | 66.0 |
Analysis of Variance | 13 | 0.0 |
Fibrinolysis/*drug effects | 14 | 21.0 |
Fibrinolytic Agents/*administration & dosage | 6 | 50.0 |
Blood Coagulation Tests | 37 | 18.0 |
Cross-Over Studies | 7 | 1.0 |
Heparin, Low-Molecular-Weight/*administration & dosage | 2 | 40.0 |
Renal Dialysis/*methods | 2 | 6.0 |
Conserved Sequence | 4 | 0.0 |
Open Reading Frames | 4 | 0.0 |
Pregnancy Complications, Infectious/*virology | 2 | 15.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
*Arthroplasty, Replacement, Hip | 3 | 15.0 |
Fibrin Fibrinogen Degradation Products/*analysis | 24 | 48.0 |
Antifibrinolytic Agents/blood | 10 | 66.0 |
*Antiplasmin | 34 | 80.0 |
Solubility | 6 | 0.0 |
Thrombomodulin/blood | 4 | 11.0 |
Cell Survival | 3 | 0.0 |
Cytoplasm/metabolism | 7 | 0.0 |
Gene Products, tat/genetics/metabolism | 8 | 53.0 |
Anticoagulants/*therapeutic use | 7 | 15.0 |
Fibrin/analysis | 7 | 23.0 |
Heparin/*therapeutic use | 10 | 43.0 |
Heparin, Low-Molecular-Weight/*therapeutic use | 2 | 10.0 |
Partial Thromboplastin Time | 18 | 9.0 |
Thrombin/analysis | 11 | 61.0 |
AIDS Vaccines/administration & dosage/*immunology | 2 | 28.0 |
Antiretroviral Therapy, Highly Active | 3 | 0.0 |
Genes, Viral | 12 | 5.0 |
Vaccines, DNA/administration & dosage/*immunology | 2 | 28.0 |
Viral Load | 2 | 0.0 |
*Blood | 2 | 4.0 |
Blood Cell Count | 8 | 3.0 |
Complement 3a/analysis | 2 | 11.0 |
Endothelium, Vascular/*immunology | 3 | 3.0 |
Swine | 3 | 0.0 |
Antithrombin III/drug effects/metabolism | 3 | 75.0 |
Cardiac Surgical Procedures | 2 | 10.0 |
Catheter Ablation/*adverse effects | 3 | 30.0 |
Heparin/administration & dosage | 5 | 21.0 |
Hemostatics/*blood | 2 | 50.0 |
Syndrome | 11 | 0.0 |
Blood Loss, Surgical | 4 | 14.0 |
Cardiopulmonary Bypass/*instrumentation | 3 | 23.0 |
Fibrinolysis/physiology | 15 | 34.0 |
Linear Models | 5 | 1.0 |
Adenosine Diphosphate/pharmacology | 2 | 1.0 |
Prothrombin Time | 21 | 19.0 |
Enzyme Activation | 15 | 0.0 |
HIV Infections/*virology | 8 | 8.0 |
Oxidation-Reduction | 2 | 0.0 |
Signal Transduction | 12 | 0.0 |
Virus Replication/physiology | 4 | 17.0 |
Antifibrinolytic Agents/analysis | 14 | 87.0 |
Disseminated Intravascular Coagulation/*blood/complications/diagnosis | 2 | 100.0 |
Endothelium, Vascular/pathology | 3 | 2.0 |
Neoplasms/blood/complications | 2 | 50.0 |
Sepsis/blood/complications | 2 | 50.0 |
*Gene Transfer Techniques | 4 | 1.0 |
Genes, tat/genetics | 6 | 75.0 |
*Genetic Vectors | 4 | 1.0 |
Lymphocytes/virology | 2 | 10.0 |
Promoter Regions (Genetics)/*genetics | 5 | 0.0 |
Simian virus 40/*genetics | 3 | 5.0 |
Transduction, Genetic | 9 | 2.0 |
Virus Replication/genetics | 4 | 8.0 |
Drosophila | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
RNA Polymerase II/*genetics | 2 | 25.0 |
Disease Transmission, Vertical | 2 | 2.0 |
Exons | 15 | 0.0 |
*Genes, tat | 20 | 66.0 |
Thromboplastin/*metabolism | 6 | 3.0 |
Gene Products, nef/*immunology | 2 | 20.0 |
Immunosuppressive Agents/pharmacology | 2 | 1.0 |
Dimerization | 5 | 0.0 |
Heterozygote | 4 | 0.0 |
*Models, Molecular | 5 | 4.0 |
*Mutation | 9 | 0.0 |
Protein Folding | 3 | 0.0 |
Body Mass Index | 4 | 0.0 |
Thrombin Time | 5 | 23.0 |
Cytokines/biosynthesis | 4 | 0.0 |
Disease Models, Animal | 11 | 0.0 |
Gene Products, rev/immunology | 2 | 100.0 |
Gene Products, tat/immunology | 3 | 50.0 |
Genes, env/genetics | 2 | 16.0 |
HIV-1/genetics/*immunology | 6 | 8.0 |
Immunoglobulin G/biosynthesis/blood | 2 | 20.0 |
Interferon Type II/secretion | 2 | 1.0 |
Neutralization Tests | 5 | 1.0 |
Anticoagulants/therapeutic use | 6 | 8.0 |
Antithrombins/therapeutic use | 2 | 40.0 |
Heparin/therapeutic use | 8 | 19.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Disseminated Intravascular Coagulation/*blood/complications | 5 | 100.0 |
Plasminogen Inactivators/blood | 8 | 30.0 |
P-Selectin/metabolism | 2 | 4.0 |
Platelet Factor 4/metabolism | 3 | 5.0 |
beta-Thromboglobulin/metabolism | 8 | 14.0 |
Acetyltransferases/*metabolism | 4 | 5.0 |
Gene Products, tat/*chemistry/*metabolism | 2 | 66.0 |
Terminal Repeat Sequences | 4 | 12.0 |
Platelet Count | 33 | 7.0 |
Tretinoin/*pharmacology | 3 | 0.0 |
DNA/*genetics | 2 | 0.0 |
Genetic Vectors | 21 | 1.0 |
AIDS Vaccines | 3 | 25.0 |
Autocrine Communication | 2 | 2.0 |
HIV-1/immunology/*physiology | 2 | 3.0 |
Antibodies/analysis | 2 | 1.0 |
Platelet Activation/*drug effects | 7 | 10.0 |
Protein Precursors/blood | 5 | 13.0 |
*Renal Dialysis | 9 | 2.0 |
Warfarin/therapeutic use | 3 | 10.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Endothelial Growth Factors/metabolism | 2 | 1.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Lymphokines/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 3 | 0.0 |
Receptors, Vascular Endothelial Growth Factor | 2 | 0.0 |
Vascular Endothelial Growth Factor A | 5 | 0.0 |
Vascular Endothelial Growth Factors | 5 | 0.0 |
Gene Products, tat/*chemistry | 8 | 100.0 |
United States | 3 | 0.0 |
*Nursing Research | 2 | 28.0 |
Cell Division | 7 | 0.0 |
Genes, Viral/genetics | 4 | 17.0 |
Genetic Vectors/genetics | 2 | 0.0 |
HIV Antibodies/analysis | 2 | 4.0 |
Protein Biosynthesis | 10 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 4 | 1.0 |
Transcription, Genetic/genetics | 5 | 1.0 |
Gene Products, tat | 14 | 73.0 |
*Gene Therapy | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
*HIV | 2 | 7.0 |
Viral Proteins/*pharmacology | 2 | 11.0 |
Antigens, CD95/*physiology | 2 | 2.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Antithrombins/metabolism | 7 | 43.0 |
Interleukin-1/blood | 2 | 1.0 |
Ribonucleases/metabolism | 3 | 2.0 |
Thrombin/biosynthesis | 15 | 37.0 |
Hemostasis/physiology | 9 | 28.0 |
RNA/genetics/metabolism | 2 | 1.0 |
Rats, Inbred Lew | 2 | 0.0 |
Isoproterenol/pharmacology | 2 | 1.0 |
NF-kappa B/antagonists & inhibitors | 2 | 5.0 |
Nerve Degeneration | 2 | 3.0 |
Peptides/pharmacology | 4 | 2.0 |
Rats, Wistar | 2 | 0.0 |
Recombinant Fusion Proteins/pharmacology | 3 | 3.0 |
Peptide Hydrolases/*analysis | 55 | 88.0 |
Anti-HIV Agents/*pharmacology | 7 | 5.0 |
Cell Division/drug effects | 7 | 0.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Zidovudine/*pharmacology | 2 | 7.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Antithrombin III/biosynthesis | 2 | 100.0 |
Fibrinopeptide A/analysis | 23 | 56.0 |
Plant Proteins/pharmacology | 2 | 18.0 |
Receptors, Thrombin | 5 | 10.0 |
Cell Line, Transformed | 14 | 0.0 |
Histone Deacetylases/antagonists & inhibitors | 2 | 4.0 |
Hydroxamic Acids/pharmacology | 2 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 6 | 0.0 |
*Virus Integration | 4 | 5.0 |
Gene Products, tat/chemistry/*metabolism | 12 | 85.0 |
CHO Cells | 11 | 0.0 |
Hamsters | 15 | 0.0 |
*Genetics, Population | 2 | 0.0 |
*Haplotypes | 3 | 1.0 |
Drug Synergism | 9 | 0.0 |
*Membrane Glycoproteins | 4 | 0.0 |
Neuroprotective Agents/pharmacology | 2 | 5.0 |
Drug Delivery Systems | 4 | 4.0 |
Gene Therapy/*methods | 5 | 1.0 |
*Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Aneurysm, Dissecting/blood/*surgery | 2 | 100.0 |
*Coated Materials, Biocompatible | 3 | 21.0 |
Coronary Artery Bypass | 4 | 7.0 |
Extracorporeal Circulation/*instrumentation | 2 | 66.0 |
Fibrinolysis/drug effects | 6 | 15.0 |
Blood Loss, Surgical/prevention & control | 2 | 25.0 |
*Cardiac Surgical Procedures | 3 | 6.0 |
Anticoagulants/*pharmacology/therapeutic use | 3 | 42.0 |
*Circadian Rhythm | 2 | 0.0 |
Coronary Angiography | 5 | 2.0 |
Lipoprotein(a)/*blood | 6 | 6.0 |
Retrospective Studies | 10 | 0.0 |
Genes, tat | 16 | 57.0 |
Virus Replication/*physiology | 6 | 11.0 |
*Heparin | 3 | 23.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
*Stents | 2 | 3.0 |
Remission Induction | 5 | 0.0 |
Thromboembolism/etiology | 3 | 20.0 |
Chickens | 5 | 0.0 |
Dogs | 5 | 0.0 |
HIV/*genetics | 14 | 24.0 |
*Signal Transduction | 2 | 0.0 |
Gene Products, tat/*genetics/*metabolism | 5 | 100.0 |
HIV-1/genetics/physiology | 2 | 15.0 |
*Receptors, Cell Surface | 9 | 2.0 |
Antithrombin III/drug effects | 2 | 66.0 |
Thrombin/physiology | 2 | 5.0 |
Antithrombins/*therapeutic use | 3 | 100.0 |
Pilot Projects | 5 | 0.0 |
Serine Proteinase Inhibitors/*therapeutic use | 2 | 25.0 |
Aspirin/therapeutic use | 2 | 5.0 |
Cerebral Angiography | 2 | 7.0 |
Fibrinolytic Agents/therapeutic use | 4 | 22.0 |
Hospitalization | 2 | 1.0 |
Plasminogen Activator Inhibitor 1/analysis | 4 | 12.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 15 | 5.0 |
*Genes, MHC Class II | 2 | 0.0 |
HIV-1/*genetics/physiology | 10 | 38.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
Drug Design | 6 | 1.0 |
*Balloon Dilatation | 2 | 33.0 |
Hemodynamic Processes | 3 | 1.0 |
Biological Transport | 9 | 0.0 |
Endocytosis | 4 | 1.0 |
Fetus | 2 | 0.0 |
LDL-Receptor Related Protein 1 | 2 | 1.0 |
Neurons/*metabolism | 2 | 0.0 |
PC12 Cells | 2 | 0.0 |
Receptors, Immunologic/*metabolism | 2 | 1.0 |
alpha-Macroglobulins/metabolism | 2 | 4.0 |
*Antifibrinolytic Agents | 11 | 52.0 |
Fibrinopeptide A/metabolism | 9 | 36.0 |
Placebos | 2 | 0.0 |
Adsorption | 3 | 1.0 |
Multivariate Analysis | 5 | 0.0 |
Procollagen/blood | 2 | 6.0 |
Protein C/analysis | 15 | 27.0 |
Tissue Plasminogen Activator/analysis | 6 | 15.0 |
Mitochondria/*metabolism | 2 | 1.0 |
Viral Proteins/genetics/metabolism | 2 | 5.0 |
Codon | 2 | 0.0 |
*Genome, Viral | 3 | 4.0 |
Heart Catheterization | 2 | 3.0 |
Disseminated Intravascular Coagulation/*blood | 8 | 38.0 |
Lipoproteins/*metabolism | 2 | 1.0 |
Amino Acid Substitution | 7 | 0.0 |
Calcium/metabolism | 4 | 0.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Blood Coagulation Factors/*analysis | 10 | 12.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 3 | 2.0 |
Adenocarcinoma/*blood/pathology | 2 | 25.0 |
Carcinoma, Squamous Cell/*blood/pathology | 2 | 66.0 |
Disease Progression | 2 | 0.0 |
Lung Neoplasms/*blood/pathology | 3 | 50.0 |
Neoplasm Staging | 4 | 0.0 |
Plasminogen Activator Inhibitor 1/metabolism | 7 | 14.0 |
Tissue Plasminogen Activator/metabolism | 7 | 18.0 |
Blood Coagulation | 23 | 13.0 |
Collagen/*metabolism | 3 | 1.0 |
Hemostatics | 2 | 50.0 |
Fibrinogen/*analysis | 2 | 4.0 |
Hemoglobin A, Glycosylated/analysis | 2 | 0.0 |
Lipoprotein(a)/blood | 2 | 3.0 |
Trans-Activators/isolation & purification/metabolism | 2 | 40.0 |
Superoxides/metabolism | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
Chromatography, Affinity | 3 | 0.0 |
Escherichia coli/genetics | 6 | 1.0 |
HIV-1/*chemistry | 7 | 24.0 |
Fibrinolytic Agents/blood | 2 | 16.0 |
Platelet Activating Factor/metabolism | 2 | 12.0 |
Fluorescent Dyes | 4 | 1.0 |
RNA, Viral/chemistry/*metabolism | 7 | 58.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Disseminated Intravascular Coagulation/blood | 6 | 31.0 |
Myocardial Infarction/blood | 2 | 5.0 |
Pulmonary Embolism/blood | 3 | 42.0 |
Venous Thrombosis/blood | 2 | 33.0 |
Sequence Analysis | 4 | 1.0 |
Tyrosine Transaminase/*genetics | 15 | 93.0 |
Thromboplastin/*biosynthesis | 2 | 2.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
HIV-1/*drug effects/genetics/physiology | 3 | 14.0 |
Virus Replication/*drug effects | 9 | 5.0 |
Angioplasty, Transluminal, Percutaneous Coronary/*adverse effects | 2 | 15.0 |
Lipoproteins/blood | 6 | 1.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Escherichia coli | 3 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Trans-Activators/chemistry/genetics/*metabolism | 2 | 2.0 |
Adenoviridae/genetics | 4 | 0.0 |
COS Cells | 15 | 0.0 |
Cattle | 8 | 0.0 |
Aprotinin/*pharmacology | 2 | 20.0 |
*Cardiopulmonary Bypass | 9 | 9.0 |
*Drug Design | 2 | 2.0 |
Gene Expression/drug effects | 4 | 0.0 |
RNA, Messenger/antagonists & inhibitors | 2 | 9.0 |
Survival Rate | 3 | 0.0 |
Heart Valve Prosthesis | 2 | 15.0 |
Plasmin/*analysis | 7 | 63.0 |
Protein S/analysis | 8 | 23.0 |
Thromboembolism/blood | 2 | 25.0 |
Antifibrinolytic Agents/*analysis | 4 | 50.0 |
Disseminated Intravascular Coagulation/blood/*diagnosis | 3 | 75.0 |
G1 Phase | 2 | 0.0 |
Nuclear Proteins/metabolism | 3 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 7 | 0.0 |
T-Lymphocytes/cytology | 2 | 2.0 |
Gene Therapy/methods | 3 | 3.0 |
Liver Function Tests | 2 | 1.0 |
Lipoproteins/*blood | 4 | 0.0 |
Renal Dialysis/*adverse effects | 8 | 5.0 |
Thrombomodulin/*blood | 3 | 11.0 |
Anemia, Sickle Cell/*blood | 2 | 6.0 |
Carbohydrate Sequence | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 8 | 0.0 |
Protein Binding/drug effects | 5 | 1.0 |
RNA, Viral/*chemistry | 2 | 40.0 |
Tissue Plasminogen Activator/blood/immunology | 2 | 66.0 |
alpha 1-Antitrypsin/metabolism | 3 | 6.0 |
Indicators and Reagents | 4 | 1.0 |
Fungal Proteins/metabolism | 4 | 2.0 |
Glutathione Transferase/genetics/metabolism | 4 | 3.0 |
Point Mutation | 11 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/metabolism | 2 | 2.0 |
Gene Products, tat/*genetics/physiology | 3 | 100.0 |
TATA Box | 7 | 2.0 |
Japan | 4 | 0.0 |
Thrombophlebitis/*blood/*drug therapy | 2 | 100.0 |
Heparin/*pharmacology | 4 | 2.0 |
Genetic Complementation Test | 5 | 0.0 |
Leukocytes, Mononuclear/cytology | 2 | 4.0 |
RNA, Viral | 6 | 14.0 |
HIV Infections/*metabolism | 2 | 4.0 |
Heart Arrest, Induced | 2 | 20.0 |
Lipids/metabolism | 2 | 0.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
Laboratories/*standards | 2 | 8.0 |
Quality Control | 3 | 1.0 |
Diagnosis, Differential | 6 | 0.0 |
Emergency Service, Hospital | 2 | 16.0 |
Thrombin/*analysis | 11 | 73.0 |
Birth Weight | 2 | 1.0 |
Response Elements | 2 | 0.0 |
*Terminal Repeat Sequences | 2 | 22.0 |
*Blood Transfusion | 2 | 1.0 |
Transplantation, Homologous | 3 | 0.0 |
Gene Products, tat/genetics/*pharmacology | 3 | 60.0 |
Heparin/pharmacology | 7 | 2.0 |
Recombinant Fusion Proteins | 5 | 1.0 |
Blood Transfusion | 2 | 1.0 |
Intraoperative Period | 6 | 10.0 |
Antithrombin III/*metabolism | 33 | 53.0 |
Immunoelectrophoresis | 3 | 1.0 |
Peptide Hydrolases/*metabolism | 31 | 31.0 |
Binding Sites/genetics | 10 | 1.0 |
HIV-1/*pathogenicity | 2 | 2.0 |
Immunohistochemistry | 7 | 0.0 |
*Complement Inactivators | 2 | 2.0 |
*Glycoproteins | 2 | 0.0 |
Protein S/metabolism | 5 | 14.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Escherichia coli/enzymology | 2 | 3.0 |
Protein Conformation | 13 | 0.0 |
Protein Structure, Secondary | 5 | 0.0 |
Structure-Activity Relationship | 23 | 0.0 |
Gene Products, tat/*antagonists & inhibitors | 6 | 85.0 |
HIV Long Terminal Repeat/*drug effects | 2 | 25.0 |
Trans-Activation (Genetics)/drug effects | 10 | 4.0 |
Thromboplastin/metabolism | 4 | 5.0 |
Aortic Aneurysm, Abdominal/*physiopathology/surgery | 2 | 100.0 |
Kidney/*blood supply | 2 | 20.0 |
Preoperative Care/methods | 2 | 7.0 |
*CCAAT-Enhancer-Binding Proteins | 4 | 3.0 |
Gene Expression Regulation | 15 | 0.0 |
DNA, Viral | 10 | 6.0 |
Gene Products, env/genetics | 2 | 13.0 |
Gene Products, rev/genetics | 5 | 62.0 |
*Regulatory Sequences, Nucleic Acid | 12 | 3.0 |
Myocardial Infarction/blood/*drug therapy | 4 | 28.0 |
Platelet Aggregation/*drug effects | 3 | 2.0 |
Streptokinase/therapeutic use | 3 | 42.0 |
*Thrombolytic Therapy | 6 | 27.0 |
Tissue Plasminogen Activator/therapeutic use | 3 | 42.0 |
3T3 Cells | 9 | 0.0 |
Cell Cycle Proteins/*metabolism | 3 | 0.0 |
Gene Expression Regulation, Viral/*genetics | 3 | 18.0 |
RNA-Binding Proteins/metabolism | 4 | 4.0 |
Viral Proteins/metabolism | 2 | 2.0 |
Blood Proteins/metabolism | 3 | 1.0 |
Cell Membrane/*metabolism | 4 | 1.0 |
*Amino Acid Substitution | 2 | 2.0 |
Astrocytes | 2 | 20.0 |
HIV Infections/therapy | 3 | 20.0 |
Virus Replication/*genetics | 10 | 30.0 |
Fibrinolytic Agents/*therapeutic use | 3 | 12.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 9 | 5.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Gene Expression Regulation, Viral/*drug effects | 5 | 17.0 |
Glucocorticoids/*pharmacology | 3 | 1.0 |
Receptors, Glucocorticoid/metabolism | 3 | 5.0 |
T-Lymphocytes | 8 | 3.0 |
Trans-Activators/metabolism | 4 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 6 | 0.0 |
U937 Cells | 3 | 0.0 |
Cyclic GMP/blood | 2 | 14.0 |
Peptide Hydrolases | 2 | 10.0 |
Platelet Aggregation/drug effects | 4 | 1.0 |
Preoperative Care/*methods | 2 | 22.0 |
Cyclin-Dependent Kinases/genetics/*metabolism | 3 | 4.0 |
Fungal Proteins/genetics/metabolism | 2 | 2.0 |
HIV/genetics | 3 | 7.0 |
TATA-Box Binding Protein | 8 | 2.0 |
Plasmids/genetics | 11 | 2.0 |
Sepsis/*blood | 2 | 10.0 |
Genes, Dominant | 3 | 0.0 |
*Genes, gag | 2 | 40.0 |
Serum Albumin/analysis | 2 | 1.0 |
alpha-Macroglobulins/analysis | 3 | 7.0 |
Base Composition | 3 | 1.0 |
Hydrogen Bonding | 6 | 3.0 |
Models, Chemical | 4 | 1.0 |
Solutions | 2 | 1.0 |
Chloroquine/pharmacology | 2 | 2.0 |
Luciferases/biosynthesis/genetics | 2 | 3.0 |
Peptide Fragments/*chemistry | 2 | 6.0 |
Excitatory Amino Acid Agonists/pharmacology | 2 | 12.0 |
N-Methylaspartate/pharmacology | 2 | 14.0 |
Rats, Sprague-Dawley | 7 | 0.0 |
Recombinant Proteins/pharmacology | 9 | 0.0 |
Cell Nucleus/genetics | 2 | 6.0 |
Exons/genetics | 3 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid/genetics | 2 | 2.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Protein Precursors/metabolism | 4 | 3.0 |
Cost-Benefit Analysis | 2 | 1.0 |
Reproducibility of Results | 6 | 0.0 |
C-Reactive Protein/analysis | 4 | 0.0 |
HIV-2/genetics/*metabolism | 2 | 50.0 |
SIV/genetics/*metabolism | 2 | 33.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Thrombosis/*diagnosis/etiology | 2 | 50.0 |
DNA/genetics | 5 | 0.0 |
Haplotypes | 2 | 0.0 |
Photochemistry | 2 | 3.0 |
DNA Footprinting | 3 | 1.0 |
Factor Xa/metabolism | 2 | 3.0 |
Biological Markers/*blood | 13 | 7.0 |
RNA Processing, Post-Transcriptional | 2 | 1.0 |
RNA, Messenger/biosynthesis | 8 | 0.0 |
RNA, Viral/*biosynthesis | 4 | 19.0 |
RNA, Viral/genetics/*metabolism | 6 | 50.0 |
Recombinant Fusion Proteins/biosynthesis | 9 | 2.0 |
Sequence Deletion | 13 | 0.0 |
Echocardiography | 4 | 1.0 |
Linkage (Genetics) | 5 | 0.0 |
Tumor Necrosis Factor-alpha/*analysis | 3 | 1.0 |
Endothelium, Vascular/*chemistry/*pathology | 4 | 100.0 |
Immunoassay | 2 | 0.0 |
Tissue Plasminogen Activator/analysis/blood | 2 | 66.0 |
von Willebrand Factor/analysis | 8 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
Heparin Cofactor II/analysis | 3 | 60.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Cell Nucleus | 5 | 6.0 |
Cytoplasm | 4 | 6.0 |
Circular Dichroism | 6 | 1.0 |
Gene Products, tat/*chemistry/metabolism | 2 | 100.0 |
eIF-2 Kinase/metabolism | 2 | 14.0 |
HIV-1/metabolism/*pathogenicity | 2 | 11.0 |
Antifibrinolytic Agents/blood/metabolism | 2 | 100.0 |
Factor VII/metabolism | 3 | 7.0 |
Hemofiltration/*adverse effects | 2 | 66.0 |
Blood Coagulation Disorders/blood/*complications | 2 | 66.0 |
Neoplasms/*blood/complications | 4 | 36.0 |
5' Untranslated Regions | 2 | 1.0 |
Gene Products, gag/genetics | 2 | 10.0 |
*RNA, Viral | 2 | 15.0 |
Blood Specimen Collection | 2 | 4.0 |
HIV Infections/*immunology | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 6 | 1.0 |
Immunity, Cellular | 2 | 0.0 |
Cell Survival/drug effects | 3 | 0.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis/genetics | 4 | 12.0 |
Genes, Reporter/genetics | 4 | 1.0 |
HIV-1/*drug effects/genetics | 5 | 16.0 |
Protein Biosynthesis/*drug effects | 2 | 6.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
Platelet Factor 4/analysis | 6 | 7.0 |
Recombinant Proteins/administration & dosage | 5 | 5.0 |
Streptokinase/*administration & dosage | 2 | 100.0 |
Tissue Plasminogen Activator/*administration & dosage | 3 | 100.0 |
Fetal Growth Retardation/*etiology | 2 | 18.0 |
Thrombosis/blood/etiology | 2 | 16.0 |
Biocompatible Materials | 3 | 4.0 |
Cross-Linking Reagents | 3 | 0.0 |
Fluorescein-5-isothiocyanate | 3 | 2.0 |
Signal Transduction/genetics | 2 | 0.0 |
Genome, Viral | 5 | 3.0 |
Macrophage Colony-Stimulating Factor/*blood | 2 | 22.0 |
Cysteine/metabolism | 3 | 3.0 |
Epitopes, B-Lymphocyte/*immunology | 2 | 16.0 |
HIV-1/metabolism | 7 | 14.0 |
Models, Statistical | 2 | 1.0 |
Antigens, CD4/genetics/metabolism | 2 | 9.0 |
Chromosomes, Human, Pair 12 | 2 | 1.0 |
Quantitative Structure-Activity Relationship | 2 | 6.0 |
Prothrombin/*genetics | 2 | 3.0 |
Fibronectins/metabolism | 2 | 1.0 |
In Situ Hybridization | 3 | 0.0 |
Convalescence | 3 | 9.0 |
*Cyclin-Dependent Kinases | 3 | 1.0 |
Protein-Serine-Threonine Kinases/physiology | 3 | 3.0 |
RNA, Viral/analysis | 3 | 1.0 |
*Apoptosis | 5 | 0.0 |
CD4-Positive T-Lymphocytes/virology | 3 | 4.0 |
Diabetes Complications | 2 | 1.0 |
Evaluation Studies | 5 | 0.0 |
*HIV-1/genetics | 3 | 5.0 |
*Protein Conformation | 2 | 0.0 |
Recombinant Proteins | 5 | 0.0 |
Staining and Labeling | 2 | 0.0 |
Interleukin-8/blood | 3 | 3.0 |
Arginine/chemistry | 2 | 3.0 |
Gene Products, tat/*chemistry/genetics/*metabolism | 3 | 100.0 |
Gene Expression Regulation, Viral/*physiology | 4 | 25.0 |
HIV/*genetics/physiology | 2 | 50.0 |
Gene Products, gag/biosynthesis | 2 | 25.0 |
Gene Products, tat/*biosynthesis | 3 | 100.0 |
*Protein Biosynthesis | 4 | 0.0 |
Sheep | 3 | 0.0 |
Visna-maedi virus/*genetics | 2 | 100.0 |
Fibrinopeptide A/*analysis | 8 | 47.0 |
Heparin/*administration & dosage/therapeutic use | 2 | 100.0 |
Thrombosis/*etiology | 4 | 8.0 |
Plasminogen Activator Inhibitor 1/*blood | 3 | 9.0 |
Pregnancy/*blood | 12 | 7.0 |
Pregnancy Complications, Cardiovascular/*blood | 2 | 9.0 |
RNA, Viral/genetics | 8 | 9.0 |
RNA-Binding Proteins/genetics | 2 | 3.0 |
Trans-Activation (Genetics)/genetics | 5 | 5.0 |
Zinc/*metabolism | 2 | 3.0 |
HIV Infections/*prevention & control | 2 | 7.0 |
Trans-Activation (Genetics)/*drug effects | 7 | 7.0 |
Heparin/*metabolism/pharmacology | 2 | 15.0 |
Thrombomodulin/metabolism | 3 | 10.0 |
Coronary Artery Bypass/adverse effects | 2 | 50.0 |
Genes, env | 3 | 5.0 |
Safety | 2 | 1.0 |
Gene Products, tat/physiology | 6 | 35.0 |
Trans-Activators/*physiology | 3 | 1.0 |
*Esophagectomy | 2 | 40.0 |
Leukocyte Elastase/blood | 3 | 25.0 |
Acetyltransferases/antagonists & inhibitors/genetics/metabolism | 2 | 100.0 |
DNA Primers/genetics | 4 | 0.0 |
*Genes, MHC Class I | 2 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 3 | 0.0 |
Repressor Proteins/metabolism | 2 | 1.0 |
Saccharomyces cerevisiae/genetics | 5 | 1.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
*Enhancer Elements (Genetics) | 6 | 2.0 |
*TATA Box | 2 | 1.0 |
Gene Products, tat/genetics/isolation & purification/*metabolism | 2 | 100.0 |
Cercopithecus aethiops | 8 | 0.0 |
Molecular Conformation | 3 | 1.0 |
NF-kappa B/metabolism | 11 | 1.0 |
Astrocytoma | 2 | 5.0 |
Gene Products, tat/*genetics/pharmacology | 3 | 100.0 |
HIV-1/*genetics/immunology | 2 | 8.0 |
Radioligand Assay | 2 | 0.0 |
Ukraine | 2 | 7.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
HIV Enhancer | 2 | 50.0 |
RNA, Viral/chemistry/metabolism | 2 | 50.0 |
Adenosylhomocysteinase | 2 | 13.0 |
HIV-1/genetics | 6 | 10.0 |
Hydrolases/*antagonists & inhibitors | 2 | 40.0 |
Transfection/genetics | 3 | 2.0 |
Disseminated Intravascular Coagulation/*blood/etiology | 5 | 45.0 |
Cerebral Hemorrhage/chemically induced | 2 | 100.0 |
Infant, Premature | 2 | 1.0 |
Incidence | 2 | 0.0 |
Karyotyping | 4 | 0.0 |
Disseminated Intravascular Coagulation/*diagnosis | 6 | 75.0 |
Liver Cirrhosis/*blood | 3 | 8.0 |
Alternative Splicing | 2 | 0.0 |
Gene Products, tat/genetics | 10 | 47.0 |
Nuclear Proteins/*genetics | 3 | 0.0 |
Antiplasmin/*metabolism | 4 | 66.0 |
Antithrombins/*analysis | 2 | 22.0 |
Creatinine/blood | 2 | 0.0 |
Prothrombin/*analysis | 16 | 51.0 |
Gene Products, tax/genetics/*metabolism | 2 | 15.0 |
HIV-1/*genetics/*metabolism/physiology | 2 | 100.0 |
Endothelium, Vascular/physiopathology | 3 | 8.0 |
Thromboplastin/*analysis/physiology | 2 | 40.0 |
Polymerase Chain Reaction | 17 | 0.0 |
Protein Kinases/metabolism | 3 | 0.0 |
RNA, Double-Stranded/metabolism | 2 | 12.0 |
Protein C/antagonists & inhibitors/*metabolism | 2 | 22.0 |
Proteins/analysis | 2 | 1.0 |
Gene Products, tat/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Heparin/*metabolism | 3 | 3.0 |
Injections, Intraventricular | 2 | 1.0 |
Cell Differentiation/drug effects | 4 | 0.0 |
Repetitive Sequences, Nucleic Acid | 14 | 1.0 |
Transcription Factor, Sp1/*metabolism | 4 | 1.0 |
Cytokines/*biosynthesis | 2 | 0.0 |
HIV-1/*drug effects | 5 | 3.0 |
Intercellular Adhesion Molecule-1/analysis | 2 | 1.0 |
Blotting, Northern | 8 | 0.0 |
Leg/*blood supply | 3 | 9.0 |
Antibodies, Anticardiolipin/blood | 2 | 7.0 |
Lupus Coagulation Inhibitor/blood | 2 | 15.0 |
Alanine Transaminase/blood | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Thrombin/*antagonists & inhibitors | 2 | 16.0 |
Antithrombin III/analysis/metabolism | 4 | 80.0 |
*Blood Transfusion, Autologous | 2 | 8.0 |
Peptide Hydrolases/analysis/metabolism | 4 | 100.0 |
HIV-1/drug effects/*genetics/physiology | 2 | 50.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Genes, rev | 6 | 50.0 |
Mutagenesis | 8 | 0.0 |
Amino Acid Metabolism, Inborn Errors/*genetics | 2 | 5.0 |
DNA Mutational Analysis | 14 | 0.0 |
Italy | 2 | 0.0 |
Pedigree | 3 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Tyrosine/*blood | 3 | 7.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Pre-Eclampsia/*blood | 2 | 4.0 |
Gene Products, tat/chemistry | 2 | 100.0 |
Arginine/metabolism | 2 | 3.0 |
Gene Products, tat/chemical synthesis/*metabolism | 3 | 100.0 |
Peptide Fragments/chemical synthesis/metabolism | 2 | 18.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 1.0 |
*Acetyltransferases | 2 | 13.0 |
HIV Antibodies/*immunology | 5 | 5.0 |
Macaca mulatta | 7 | 1.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Recombinant Fusion Proteins/genetics | 3 | 1.0 |
Cytomegalovirus/*genetics | 2 | 5.0 |
Fluorescent Antibody Technique | 13 | 0.0 |
Trans-Activators/genetics | 3 | 1.0 |
*Chemotaxis, Leukocyte | 2 | 2.0 |
DNA-Binding Proteins/*physiology | 4 | 0.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Plasminogen Activator Inhibitor 2/blood | 2 | 100.0 |
Fibrin/*metabolism | 4 | 10.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 3 | 2.0 |
Genes, fos | 2 | 1.0 |
Recombination, Genetic | 4 | 0.0 |
Blood Coagulation Disorders/*physiopathology | 2 | 40.0 |
Necrosis | 4 | 1.0 |
Cellulose/analogs & derivatives | 2 | 6.0 |
Equipment Design | 3 | 2.0 |
*Membranes, Artificial | 6 | 7.0 |
Renal Dialysis/*instrumentation | 2 | 16.0 |
Anticoagulants/adverse effects/*therapeutic use | 2 | 28.0 |
Peptide Fragments/*analysis | 14 | 28.0 |
Postpartum Period/blood | 3 | 15.0 |
Cytosol/metabolism | 2 | 0.0 |
Peptides/metabolism | 5 | 2.0 |
Aprotinin/*therapeutic use | 4 | 40.0 |
DNA, Complementary | 3 | 0.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
Transcription Factor, Sp1/metabolism | 7 | 2.0 |
Enzyme Induction | 2 | 0.0 |
Stereoisomerism | 2 | 0.0 |
RNA, Messenger/genetics | 15 | 0.0 |
HIV Long Terminal Repeat/genetics/*physiology | 2 | 66.0 |
Surface Properties | 4 | 2.0 |
CD4-Positive T-Lymphocytes/metabolism | 2 | 1.0 |
*Trans-Activators | 2 | 0.0 |
Contrast Media/*pharmacology | 2 | 33.0 |
Protein Precursors/*analysis | 2 | 8.0 |
Specimen Handling | 2 | 2.0 |
DNA, Viral/genetics | 6 | 3.0 |
Gene Products, rev/metabolism | 2 | 40.0 |
HIV-1/*genetics/growth & development | 3 | 25.0 |
T-Lymphocytes/virology | 2 | 2.0 |
Angiography, Digital Subtraction | 2 | 18.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Ligation | 2 | 2.0 |
Postoperative Complications/prevention & control | 3 | 10.0 |
*Sclerotherapy | 2 | 18.0 |
Spodoptera | 2 | 0.0 |
HIV/*metabolism | 5 | 13.0 |
*Trans-Activation (Genetics)/drug effects | 2 | 4.0 |
Lung Neoplasms/*blood | 2 | 9.0 |
*Adaptation, Physiological | 2 | 3.0 |
Alanine | 2 | 2.0 |
Cell Extracts | 2 | 1.0 |
Cell Nucleus/chemistry | 3 | 1.0 |
Gene Expression Regulation, Viral/physiology | 3 | 12.0 |
Trans-Activation (Genetics)/*physiology | 3 | 2.0 |
Drug Interactions | 6 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Proteins/*metabolism | 3 | 0.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 8 | 5.0 |
Cysteine | 3 | 2.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
RNA-Binding Proteins/*metabolism | 4 | 4.0 |
Introns | 4 | 0.0 |
Proviruses/genetics/physiology | 2 | 20.0 |
Gene Products, tat/biosynthesis/*metabolism | 4 | 66.0 |
Virus Replication/drug effects | 6 | 2.0 |
RNA, Viral/*genetics | 11 | 25.0 |
Mice, Inbred Strains | 2 | 0.0 |
Thrombosis/blood | 3 | 15.0 |
Liver/enzymology | 3 | 0.0 |
Oocytes/metabolism | 2 | 1.0 |
Xenopus laevis | 2 | 0.0 |
Diabetic Nephropathies/*blood | 3 | 15.0 |
Thrombomodulin/*metabolism | 2 | 8.0 |
Hemostasis/drug effects | 3 | 9.0 |
Complement 3/metabolism | 2 | 0.0 |
Centrifugation | 2 | 2.0 |
Complement Hemolytic Activity Assay | 2 | 4.0 |
L-Lactate Dehydrogenase/blood | 2 | 1.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Epitopes, T-Lymphocyte/*immunology | 2 | 3.0 |
Gene Products, tat/genetics/*immunology | 2 | 100.0 |
Oligodeoxyribonucleotides | 12 | 1.0 |
Cell Compartmentation | 5 | 1.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
HIV-1/*genetics/pathogenicity | 3 | 23.0 |
CCAAT-Enhancer-Binding Proteins | 3 | 1.0 |
Interleukin-6/*biosynthesis | 2 | 1.0 |
Oligonucleotide Probes | 4 | 0.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Administration, Intranasal | 2 | 2.0 |
HIV Antibodies/*biosynthesis | 2 | 15.0 |
Cations | 3 | 3.0 |
*Liposomes | 2 | 5.0 |
Heparin/administration & dosage/*therapeutic use | 2 | 100.0 |
Prothrombin/*metabolism | 9 | 28.0 |
*Antithrombin III Deficiency | 9 | 56.0 |
Transcription Factors/isolation & purification/*metabolism | 2 | 3.0 |
*Up-Regulation | 2 | 0.0 |
Factor VIIa/*metabolism | 2 | 5.0 |
Lupus Coagulation Inhibitor/*blood | 2 | 15.0 |
Peptide Fragments/*metabolism | 8 | 5.0 |
Coronary Disease/*blood | 3 | 4.0 |
Factor VII/*metabolism | 5 | 22.0 |
Bleeding Time | 4 | 3.0 |
Drug Evaluation | 2 | 0.0 |
Pancreatic Elastase/blood | 3 | 12.0 |
Cell Differentiation | 2 | 0.0 |
Gene Products, gag/analysis | 2 | 8.0 |
Macrophages/immunology/*virology | 2 | 15.0 |
Retroviridae/genetics | 5 | 1.0 |
Protein Kinase C/metabolism | 2 | 0.0 |
eIF-2 Kinase | 3 | 18.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Multienzyme Complexes/*metabolism | 2 | 1.0 |
*Muscle Proteins | 2 | 0.0 |
Peptide Fragments/chemistry/metabolism | 3 | 2.0 |
Blood Coagulation/*immunology | 2 | 22.0 |
Fibrinolysis/*immunology | 3 | 60.0 |
T-Lymphocytes/metabolism/*virology | 2 | 10.0 |
*Liver Transplantation | 2 | 1.0 |
Polypyrimidine Tract-Binding Protein | 2 | 25.0 |
Sarcoma Viruses, Avian/genetics | 2 | 10.0 |
Autoantibodies/*analysis | 5 | 2.0 |
Spermatozoa/*immunology | 12 | 28.0 |
HIV-1/*chemistry/genetics | 2 | 66.0 |
CD4-Positive T-Lymphocytes | 2 | 0.0 |
Coculture Techniques | 3 | 0.0 |
Fungal Proteins/biosynthesis | 2 | 14.0 |
Peptide Fragments/*pharmacology | 3 | 1.0 |
RNA, Viral/biosynthesis | 3 | 6.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 3 | 0.0 |
Antithrombin III/*analysis/immunology | 2 | 66.0 |
Evolution, Molecular | 2 | 0.0 |
*Chromosomes, Human, Pair 16 | 5 | 2.0 |
Myocardial Infarction/*drug therapy | 2 | 12.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Genes, tat/*genetics | 4 | 80.0 |
RNA, Antisense/genetics | 2 | 8.0 |
Isoquinolines/pharmacology | 2 | 1.0 |
*Angioplasty, Transluminal, Percutaneous Coronary | 4 | 8.0 |
Contrast Media/*adverse effects | 3 | 20.0 |
*Coronary Angiography | 2 | 8.0 |
HIV Long Terminal Repeat/drug effects | 3 | 33.0 |
Heart-Assist Devices/*adverse effects | 2 | 40.0 |
Platelet Aggregation | 3 | 1.0 |
Thromboplastin/pharmacology | 2 | 15.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Immunoblotting | 4 | 0.0 |
Trans-Activation (Genetics)/*genetics | 5 | 5.0 |
Antiviral Agents/pharmacology | 2 | 3.0 |
Cytopathogenic Effect, Viral | 2 | 1.0 |
Haplorhini | 2 | 0.0 |
Receptors, Interleukin-4 | 2 | 2.0 |
Uremia/*blood | 2 | 6.0 |
Blood Sedimentation | 2 | 1.0 |
C-Reactive Protein/metabolism | 2 | 0.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Gene Products, tat/pharmacology | 4 | 40.0 |
Signal Transduction/physiology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 3 | 0.0 |
*Point Mutation | 3 | 0.0 |
Fibrin/*chemistry | 2 | 40.0 |
Stress, Psychological/blood | 2 | 33.0 |
Gene Products, tax/genetics/metabolism | 2 | 66.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
TATA Box/*genetics | 3 | 12.0 |
Smoking/*blood | 2 | 8.0 |
*Aged | 2 | 4.0 |
Biopterin/analogs & derivatives/blood | 2 | 4.0 |
Inflammation | 2 | 0.0 |
Neopterin | 2 | 2.0 |
Hyperlipidemia/*blood | 2 | 5.0 |
Lipids/*blood | 2 | 0.0 |
Cricetulus | 3 | 0.0 |
Phenotype | 7 | 0.0 |
Polymorphism, Restriction Fragment Length | 5 | 0.0 |
HIV-2/*metabolism | 2 | 14.0 |
DNA, Viral/*metabolism | 2 | 6.0 |
*Repetitive Sequences, Nucleic Acid | 5 | 1.0 |
Thrombosis/*blood/etiology | 3 | 33.0 |
Transcription Factors/*genetics | 7 | 0.0 |
*Pyrroles | 3 | 75.0 |
beta-Galactosidase/genetics | 2 | 1.0 |
Antiviral Agents/*pharmacology | 8 | 5.0 |
HIV/*physiology | 2 | 2.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Ultraviolet Rays | 2 | 0.0 |
Labor, Obstetric/*blood | 2 | 16.0 |
Thrombophlebitis/blood/*diagnosis | 2 | 66.0 |
Reagent Kits, Diagnostic | 3 | 2.0 |
Hepatic Artery | 3 | 5.0 |
Operator Regions (Genetics) | 2 | 50.0 |
Gene Products, tat/biosynthesis/*genetics | 4 | 80.0 |
RNA-Binding Proteins/*genetics/metabolism | 2 | 6.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Thrombosis/*blood | 3 | 10.0 |
Antifibrinolytic Agents/*metabolism | 2 | 33.0 |
Cardiopulmonary Bypass/*adverse effects | 2 | 7.0 |
Platelet Adhesiveness | 2 | 4.0 |
*Platelet Transfusion | 2 | 8.0 |
Lymphocyte Activation | 3 | 0.0 |
Ioxaglic Acid/adverse effects | 2 | 100.0 |
Cell Division/physiology | 2 | 0.0 |
DNA, Viral/genetics/metabolism | 2 | 6.0 |
*Viral Proteins | 2 | 1.0 |
Gene Products, tat/analysis/*biosynthesis | 2 | 100.0 |
Restriction Mapping | 22 | 1.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
HIV-2/*genetics | 2 | 28.0 |
Oligoribonucleotides | 2 | 40.0 |
*Chromosomes, Human, Pair 12 | 3 | 1.0 |
Heparin/blood/*therapeutic use | 2 | 50.0 |
Cell Death | 4 | 1.0 |
Leukemia/*complications | 2 | 40.0 |
Gene Products, rev/*genetics | 2 | 40.0 |
Antibody Specificity | 2 | 0.0 |
Epitope Mapping | 7 | 2.0 |
Gene Expression Regulation, Viral/drug effects | 5 | 23.0 |
Enhancer Elements (Genetics)/genetics | 4 | 5.0 |
Infectious Anemia Virus, Equine/*genetics | 3 | 60.0 |
Prednisolone/blood/*pharmacokinetics/*pharmacology | 2 | 100.0 |
Leukocytes, Mononuclear/virology | 4 | 3.0 |
Blood Coagulation Factors/analysis | 8 | 13.0 |
Atrial Fibrillation/*complications | 2 | 100.0 |
Diabetes Mellitus, Type 2/*blood | 3 | 2.0 |
Papio | 3 | 1.0 |
Benzodiazepinones/pharmacology | 2 | 11.0 |
Pyrroles/pharmacology | 2 | 4.0 |
RNA, Viral/*genetics/metabolism | 5 | 62.0 |
Tumor Necrosis Factor-alpha/analysis | 4 | 0.0 |
HIV-1 Reverse Transcriptase | 3 | 4.0 |
RNA-Directed DNA Polymerase/metabolism | 3 | 4.0 |
Monitoring, Physiologic | 2 | 2.0 |
Tyrosine/metabolism | 2 | 0.0 |
Fungal Proteins/genetics | 2 | 1.0 |
Chimera | 2 | 1.0 |
Genes, Structural | 2 | 0.0 |
*Kallikrein-Kinin System | 2 | 66.0 |
alpha 1-Antitrypsin/analysis | 2 | 2.0 |
DNA-Binding Proteins/*genetics/metabolism | 6 | 1.0 |
Gene Expression Regulation, Viral/genetics | 2 | 13.0 |
T-Lymphocytes/*virology | 2 | 3.0 |
Myocardial Infarction/*blood/*therapy | 2 | 66.0 |
Transcription Factor TFIID | 4 | 2.0 |
Gene Products, tat/isolation & purification/*metabolism | 2 | 100.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Cytotoxicity Tests, Immunologic | 2 | 0.0 |
Computer Simulation | 2 | 0.0 |
Postoperative Complications | 2 | 1.0 |
Drug Resistance, Microbial | 3 | 1.0 |
Virus Integration/drug effects | 2 | 28.0 |
Terminator Regions (Genetics) | 2 | 7.0 |
Infusions, Intra-Arterial | 2 | 3.0 |
Thrombolytic Therapy/*adverse effects | 2 | 40.0 |
Factor XIII/*metabolism | 2 | 33.0 |
Thrombomodulin/analysis | 3 | 10.0 |
*DNA Replication | 2 | 0.0 |
Leukocyte Elastase | 4 | 9.0 |
Pancreatic Elastase/*blood | 3 | 15.0 |
Antithrombin III Deficiency | 2 | 14.0 |
Factor VIIa/*analysis | 2 | 50.0 |
Warfarin/*therapeutic use | 2 | 20.0 |
Dizocilpine Maleate/pharmacology | 2 | 11.0 |
Excitatory Amino Acid Antagonists/pharmacology | 2 | 6.0 |
Microscopy, Confocal | 3 | 0.0 |
Neural Conduction/drug effects | 2 | 15.0 |
Transcription Factors/physiology | 2 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Aortic Aneurysm, Abdominal/blood/*surgery | 2 | 40.0 |
*Blood Coagulation Tests | 3 | 13.0 |
Postoperative Complications/*blood | 2 | 9.0 |
Bacterial Proteins/*biosynthesis | 2 | 40.0 |
Membrane Proteins/*biosynthesis | 2 | 3.0 |
Models, Structural | 4 | 2.0 |
Peptide Hydrolases/drug effects/metabolism | 2 | 33.0 |
*Blood Vessel Prosthesis | 2 | 6.0 |
Blotting, Southern | 5 | 0.0 |
RNA, Antisense/genetics/*pharmacology | 2 | 40.0 |
Retroviridae/*genetics | 2 | 1.0 |
Acquired Immunodeficiency Syndrome/therapy | 3 | 37.0 |
*Genes, rev | 2 | 25.0 |
RNA, Catalytic/*metabolism | 3 | 20.0 |
Blood Coagulation Disorders/*diagnosis | 3 | 37.0 |
Plasminogen/analysis | 4 | 23.0 |
Blood Preservation | 2 | 2.0 |
Methylation | 2 | 0.0 |
Gene Products, tat/biosynthesis/genetics/*physiology | 2 | 100.0 |
HIV Long Terminal Repeat/*genetics/physiology | 2 | 66.0 |
Leukemia, Promyelocytic, Acute/blood/complications | 2 | 100.0 |
Tissue Plasminogen Activator/*blood | 3 | 9.0 |
Monocytes/*drug effects/metabolism | 2 | 2.0 |
*Genes, env | 3 | 9.0 |
Antibodies, Antinuclear/immunology | 2 | 12.0 |
Autoantibodies/*immunology | 3 | 1.0 |
Infertility, Male/*immunology | 3 | 37.0 |
*Agglutination Tests | 3 | 75.0 |
Immunoglobulin A/analysis | 5 | 3.0 |
Semen/immunology | 4 | 26.0 |
Sperm Motility | 5 | 10.0 |
*Endarterectomy, Carotid | 2 | 33.0 |
Thrombin/antagonists & inhibitors/*biosynthesis | 3 | 75.0 |
Benzodiazepinones/*pharmacology | 2 | 16.0 |
HIV-1/*growth & development | 2 | 3.0 |
Lymphocytes/microbiology | 3 | 20.0 |
Pyrroles/*pharmacology | 2 | 4.0 |
*Virus Replication/drug effects | 2 | 14.0 |
Factor VII/analysis | 4 | 13.0 |
Mathematics | 2 | 1.0 |
Gene Products, tat/immunology/*pharmacology | 2 | 66.0 |
Recombinant Proteins/immunology/pharmacology | 2 | 8.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Bacterial Proteins/genetics | 2 | 2.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Sulfhydryl Compounds/pharmacology | 2 | 11.0 |
Tyrosine Transaminase/biosynthesis | 2 | 100.0 |
Tissue Plasminogen Activator/*therapeutic use | 3 | 33.0 |
Autoimmune Diseases/*blood | 2 | 15.0 |
Disease Susceptibility | 2 | 0.0 |
Citric Acid | 2 | 5.0 |
Disseminated Intravascular Coagulation/etiology | 2 | 22.0 |
Disseminated Intravascular Coagulation/*etiology | 2 | 28.0 |
False Positive Reactions | 2 | 0.0 |
Latex Fixation Tests | 2 | 7.0 |
Oocytes | 2 | 1.0 |
Xenopus | 4 | 0.0 |
Antithrombin III/genetics | 2 | 15.0 |
Chromatin/metabolism | 2 | 0.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
Plasmin/*physiology | 2 | 28.0 |
Synovial Fluid/chemistry | 2 | 9.0 |
HIV Antigens | 2 | 6.0 |
Tissue Plasminogen Activator | 2 | 100.0 |
HIV-1/*genetics/*physiology | 2 | 40.0 |
Fibrinopeptide B/analysis | 3 | 42.0 |
Glycoproteins/blood | 2 | 3.0 |
Prevalence | 2 | 0.0 |
Vitronectin | 2 | 5.0 |
Gene Products, rev/genetics/metabolism | 2 | 66.0 |
HIV Envelope Protein gp120/metabolism | 3 | 1.0 |
HIV Envelope Protein gp41/metabolism | 2 | 8.0 |
Nephrotic Syndrome/*blood | 2 | 13.0 |
*Virus Activation | 4 | 12.0 |
*Virus Latency | 3 | 6.0 |
Plasminogen Activator Inhibitor 1/*analysis/blood | 3 | 75.0 |
Thrombomodulin/*analysis | 3 | 21.0 |
von Willebrand Factor/*analysis | 2 | 1.0 |
Tissue Plasminogen Activator/*analysis/blood | 2 | 100.0 |
DNA, Viral/genetics/isolation & purification | 3 | 11.0 |
Amino Acid Motifs | 3 | 0.0 |
Hybrid Cells/*metabolism | 2 | 16.0 |
Tyrosine Transaminase/genetics | 3 | 60.0 |
Sarcosine/analogs & derivatives/pharmacology | 2 | 40.0 |
*Enzyme-Linked Immunosorbent Assay | 3 | 3.0 |
Virus Activation | 2 | 3.0 |
Liver Neoplasms, Experimental | 2 | 4.0 |
Macrophages/microbiology | 2 | 9.0 |
Glucagon/pharmacology | 2 | 6.0 |
*Phosphoproteins | 2 | 1.0 |
Infant, Newborn, Diseases/*blood | 2 | 33.0 |
RNA, Messenger/*genetics | 5 | 1.0 |
Adenocarcinoma/blood/pathology | 2 | 33.0 |
Carcinoma, Small Cell/blood/pathology | 2 | 66.0 |
Carcinoma, Squamous Cell/blood/pathology | 2 | 33.0 |
RNA-Binding Proteins/chemistry/*metabolism | 2 | 22.0 |
Oligonucleotides/chemistry | 4 | 3.0 |
Agglutination Tests | 5 | 11.0 |
Renal Dialysis/adverse effects | 2 | 6.0 |
DNA, Recombinant/genetics | 2 | 3.0 |
Microinjections | 3 | 1.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
HIV Infections/drug therapy | 2 | 4.0 |
Receptors, Cell Surface/analysis | 3 | 3.0 |
RNA, Messenger/*genetics/metabolism | 2 | 2.0 |
Thrombosis/blood/*etiology | 2 | 28.0 |
T-Lymphocytes/*microbiology | 2 | 6.0 |
*Hepatectomy | 2 | 5.0 |
*Mutagenesis | 2 | 3.0 |
Fibrinolytic Agents/*pharmacology | 3 | 9.0 |
Polydeoxyribonucleotides/*pharmacology | 2 | 66.0 |
Amino Acid Metabolism, Inborn Errors/enzymology/*genetics | 2 | 11.0 |
Tyrosine/*metabolism | 3 | 0.0 |
DNA/analysis | 2 | 0.0 |
Mice, SCID | 2 | 0.0 |
Transformation, Genetic/genetics | 2 | 16.0 |
Human T-lymphotropic virus 1/genetics | 2 | 13.0 |
Heparin Cofactor II/*analysis | 2 | 40.0 |
Fibrinopeptide A/*metabolism | 2 | 28.0 |
*Exercise Therapy | 2 | 7.0 |
Myocardial Infarction/*blood/rehabilitation | 2 | 100.0 |
Myocardial Infarction/*blood/drug therapy | 2 | 20.0 |
Chloramphenicol O-Acetyltransferase | 2 | 5.0 |
DNA Probes | 2 | 0.0 |
HIV-1/drug effects/genetics/*growth & development | 2 | 100.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
Blood Coagulation/*drug effects/physiology | 2 | 28.0 |
Uterus/*blood supply | 2 | 8.0 |
Disseminated Intravascular Coagulation/blood/etiology | 2 | 50.0 |
Factor IX/*analysis | 2 | 66.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
Hirudins/*pharmacology | 2 | 50.0 |
Actins/genetics | 3 | 2.0 |
Plasminogen Inactivators/analysis | 2 | 14.0 |
HIV-1/genetics/pathogenicity/*physiology | 2 | 18.0 |
*Genes, Structural, Viral | 2 | 15.0 |
Reticulocytes/metabolism | 3 | 4.0 |
Chromosome Deletion | 3 | 0.0 |
Liver Cirrhosis/*complications | 2 | 9.0 |
Chromosome Mapping | 4 | 0.0 |
Electrophoresis, Capillary/*methods | 2 | 6.0 |
*Genes, Structural | 4 | 0.0 |
Fibronectins/blood | 2 | 9.0 |
Leukocytes/*physiology | 2 | 3.0 |
Antibodies/*analysis | 3 | 2.0 |
Immunologic Techniques | 2 | 0.0 |
Semen/*immunology | 3 | 25.0 |
HIV Antibodies/*analysis | 2 | 9.0 |
Goats | 2 | 2.0 |
Trans-Activators/*genetics | 8 | 2.0 |
Blood Proteins/analysis | 3 | 1.0 |
Hela Cells/metabolism | 7 | 4.0 |
Trypsin/metabolism | 2 | 1.0 |
Genes, tat/*physiology | 2 | 66.0 |
Electrostatics | 2 | 1.0 |
Trans-Activators/*chemical synthesis | 2 | 100.0 |
Zinc/metabolism | 2 | 2.0 |
RNA/genetics | 3 | 2.0 |
RNA, Antisense | 2 | 3.0 |
RNA Splicing | 3 | 0.0 |
Radioimmunoassay | 3 | 0.0 |
Trans-Activators/*pharmacology | 2 | 8.0 |
Immunosorbent Techniques | 2 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Hemagglutination Tests/methods | 2 | 66.0 |
Adenovirus Early Proteins | 2 | 2.0 |
Adenoviruses, Human/genetics | 2 | 4.0 |
*Genes, Regulator | 2 | 1.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Thrombin/analysis/*biosynthesis | 2 | 33.0 |
Chymotrypsinogen/genetics | 2 | 66.0 |
Haptoglobins/genetics | 2 | 4.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/genetics | 2 | 18.0 |
Transcription Factor, Sp1 | 2 | 5.0 |
Oncogene Proteins, Viral/*genetics | 2 | 3.0 |
Arterial Occlusive Diseases/etiology/*radiography/therapy | 2 | 9.0 |
Balloon Dilatation/methods | 2 | 8.0 |
Coronary Angiography/methods | 2 | 8.0 |
Coronary Vessels/pathology | 3 | 6.0 |
Stents/*adverse effects | 3 | 9.0 |
Microscopy, Electron | 2 | 0.0 |
DNA Restriction Enzymes | 3 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Chromosome Banding | 2 | 0.0 |
Gene Products, tat/administration & dosage/*immunology | 2 | 100.0 |
Sperm Agglutination | 2 | 66.0 |
Pre-Eclampsia/*blood/etiology | 2 | 25.0 |
Escherichia coli Proteins/blood | 2 | 100.0 |
Membrane Transport Proteins/blood | 2 | 100.0 |
*Chromosomes, Human, 16-18 | 2 | 10.0 |
*Endocytosis | 2 | 1.0 |
Sodium Azide/pharmacology | 2 | 22.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Liver Neoplasms | 2 | 0.0 |
Luminescent Proteins/genetics/metabolism | 2 | 1.0 |
Tyrosine Transaminase/metabolism | 5 | 83.0 |
Tyrosine/*blood/metabolism | 2 | 66.0 |
Tyrosine Transaminase/*deficiency | 2 | 100.0 |
Rosette Formation | 2 | 0.0 |
Transferrin/immunology | 2 | 40.0 |
Thrombophilia/blood/*etiology | 2 | 22.0 |
*Cell Membrane Permeability | 2 | 8.0 |
Peptides/*metabolism | 2 | 1.0 |
